Navigation Links
'Left-handed iron corkscrews' point the way to new weapon in battle against superbugs like MRSA
Date:11/28/2011

Scientists at the University of Warwick have taken inspiration from corkscrew structures found in nature to develop a new weapon in the fight against infections like E-coli and MRSA.

Researchers have created a new synthetic class of helix-shaped molecules which they believe could be a key tool in the worldwide battle against antibiotic resistance.

By twisting molecules around iron atoms they have created what they term 'flexicates' which are active against MRSA and E-coli - but which also appear to have low toxicity, reducing the potential for side effects if used in treatment.

The work is published in Nature Chemistry.

The new structures harness the phenomenon of 'chirality' or 'handedness' whereby the corkscrew molecules could be left-handed or right-handed.

By making the most effective 'hand' to attack a specific disease, the University of Warwick research paves the way towards a more targeted approach to killing pathogens.

In the case of E-coli and MRSA, it is the left 'hand' which is most effective.

Professor Peter Scott of the University of Warwick's chemistry department said although this particular study concentrated on flexicates' activity against MRSA and E-coli, the new method of assembly could also result in new treatments for other diseases.

"It's a whole new area of chemistry that really opens up the landscape to other practical uses.

"These new molecules are synthetically flexible, which means that with a bit of tweaking they can be put to use against a whole host of different diseases, not just bugs like MRSA which are rapidly developing resistance to traditional antibiotics.

"Flexicates are also easier to make and produce less waste than many current antibiotics."

Scientists have long been able to copy nature's corkscrew-shaped molecules in man-made structures known as helicates but they have thus far not been able to use them in fighting diseases.

One of the key issues is the problem of handedness.

Sometimes 'left-handed' molecules in drugs are the most effective at combating some disease, while sometimes the 'right-handed' version works best.

Until now, scientists working with helicates have found it difficult to make samples containing just one type of corkscrew; either the right- or left-handed twist.

But with flexicates, the University of Warwick scientists have succeeded in making samples containing just one type of twist resulting in a more targeted approach which would allow the drug dosage to be halved.

And flexicates solve other problems encountered by helicates, as they are easier to optimise for specific purposes, are better absorbed by the body and are also easier to mass-produce synthetically.

Professor Scott said: "Drugs often have this property of handedness - their molecules can exist in both right and left handed versions but the body prefers to use only one of them."

"For this reason, drug companies have to go to the trouble of making many traditional molecules as one hand only.

"What we have done is solve the 'handedness' problem for this new type of drug molecule.

"By getting the correct hand we can halve the drug dose, which has the benefits of minimising side effects and reducing waste.

"For patients, it's safer to swallow half the amount of a drug.

"Our work means that we can now make whichever hand of the corkscrew we want, depending on the job we require it to do."


'/>"/>

Contact: Anna Blackaby
a.blackaby@warwick.ac.uk
44-247-657-5910
University of Warwick
Source:Eurekalert

Related medicine news :

1. CU-Boulder led study of smoking twins points to growing influence of genetic factors
2. Life challenges prevent those with lupus from keeping doctors appointments
3. Hard times during adolescence point to health problems later in life
4. Could Airway Abnormality Point to Autism?
5. Calorie count plus points based on added sugars, sodium, and saturated and trans fats recommended as new front-of-package nutrition labeling system
6. 3 factors could point to your fate after surgery
7. Evidence points to potential roles for cognitive rehabilitation therapy in treating traumatic brain injury, but further research needed
8. Gauging General Health as Poor May Point to Dementia Risk
9. Experts Point Out Signs of Dangerous Heart Rhythm
10. Novel research set to pinpoint risk of heart attacks and strokes
11. Key signal that prompts production of insulin-producing beta cells points way toward diabetes cure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst ... third time to shed lights on the variety of topics detailing why we appreciate ... Appreciation” tackles why this career has gone from being in a major recession to ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought ... industry, from leading advocates, associations and industry leaders such as Bioness. , ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
(Date:5/27/2016)... ... ... With a team of certified experts, Validation Center is ... GMP accreditation, Validation Center is also a registered authority of the international system ... Validation Center is ISO17025 accredited and only offers its clients the latest technology, ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... LabStyle Innovations Corp . ( NASDAQ: DRIO ... that the Company,s Chief Financial Officer, Zvi Ben-David ... 1-2 in New York, NY and ... Los Angeles, CA. During his ... including the U.S. FDA Clearance and commercial launch of the ...
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... -- According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - ... valued at US$ 5.89 Bn in 2014 and is anticipated ... 2023 to reach US$ 7.99 Bn in 2023. ... free drug delivery devices and the market is estimated based ...
Breaking Medicine Technology: